NFKB1 and acute myeloid leukemia: LILRB3 recruited TNF receptor-associated factor 2 (TRAF2) and cellular FLICE-inhibitory protein (cFLIP) to activate NF-κB, supporting AML survival while suppressing T-cell function (Figure 3A) 233.